News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Transposagen Biopharmaceuticals, Inc.'s Footprint-Free™ Gene Editing System Corrects Beta-Thalassemia Disease Mutation In Human IPS Cells


8/8/2014 11:12:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Ky., Aug. 8, 2014 (GLOBE NEWSWIRE) -- In the latest demonstration of Transposagen'sFootprint-Free™ Gene Editing System, published this week in Genome Research, scientists from the University of California San Francisco corrected mutations in the HBB gene, which cause a form of Beta-thalassemia. Transposagen commercializes the Footprint-Free™ Gene Editing System, which combines the industry's most precise, efficient, and flexible site-specific nucleases, NextGEN™ CRISPRs and XTN™ TALENs, with its exclusive piggyBac™ transposon system, resulting in the only commercially-available method capable of seamless excision of resistance or reporter genes. Although Transposagen scientists were not involved in the Beta-thalassemia work, Transposagen also offers custom engineering of iPS and other cell lines on a fee-for-service basis.

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=26985.

By utilizing the Footprint-Free™ system researchers have the ability to efficiently and precisely edit as little as a single nucleotide in any genome without leaving any undesired mutations and with the ability to select for rare events. The technology can be used to correct any disease-causing mutation in cells that have been removed from a patient. The corrected cells may eventually be put back in the patient to cure or mitigate the disease. The system may also be utilized in research and development applications, such as for producing disease-specific cell lines or isogenic control cell lines.

Footprint-Free™ Gene Editing

Transposagen's Footprint-Free™ Gene Editing System, was recently utilized by researchers from University of California-San Francisco to seamlessly correct mutations in the HBB gene, which cause a form of Beta-thalassemia in iPS cells. Transposagen commercializes the technology which can be used to correct any disease-causing mutation in cells that have been removed from a patient. The corrected cells may eventually be put back in the patient to cure or mitigate the disease. The system may also be utilized in research and development applications, such as for producing disease-specific cell lines or isogenic control cell lines.

CONTACT: Jack Crawford 315-351-9115 jcrawford@transposagenbio.com

Transposagen Biopharmaceuticals, Inc. Logo

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES